Blogs

Categories

Select a Sub-Category

Films and Coatings
Pharmaceutical Packaging Components
Prefillable Systems
Self Injection Devices
Vial Containment Solutions
Washing and Sterilization
Reconstitution and Transfer Devices

Select a Sub-Category

Analytical Lab Services
Contract Manufacturing
Fill-Finish
Regulatory Support

Select a Sub-Category

Cell and Gene Therapy Packaging
Drug Development Process
Regulatory Challenges
Transitioning to Combination Products

Select a Sub-Category

Corporate Development
ESG/Sustainability
One West Team (Employee Culture)
Our Culture of Giving (Philanthropy)
Research and Development

Previous Blogs

Introducing Integrated Solutions

By Amy Kim

五月 02, 2019

Since the 2012 New England Compounding Center tragedy that linked a deadly fungal meningitis outbreak to a failure to use current good manufacturing practices (cGMP),1 compounding pharmacies have faced increasing scrutiny and regulation by the U.S. Food and Drug Administration (FDA). While registering with the FDA is still voluntary, only compounding pharmacies that register, and pass inspection, will be granted “503B” status as compounding outsourcing facilities under Section 503B of the Federal Food, Drug, and Cosmetic Act.2